Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis

Kanbay M., Solak Y., Siriopol D., Aslan G., Afsar B., Yazici D., ...More

INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.48, no.12, pp.2029-2042, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 48 Issue: 12
  • Publication Date: 2016
  • Doi Number: 10.1007/s11255-016-1387-8
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2029-2042
  • Süleyman Demirel University Affiliated: Yes


Chronic kidney disease mineral and bone disorder (CKD-MBD) is associated with increased morbidity and mortality. Several cross-sectional studies investigated the association of serum sclerostin levels with mortality and vascular calcification. We aimed to investigate the effect of sclerostin on cardiovascular events (CVE), all-cause/cardiovascular mortality and vascular calcification in patients with CKD through systematic review and meta-analysis. The primary outcome was the association between sclerostin level and development of fatal and nonfatal CVE and all-cause mortality.